Vertex Pharmaceuticals Incorporated (VRTX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Vertex Pharmaceuticals Incorporated, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Vertex Pharmaceuticals Incorporated (VRTX) has returned -1.50% so far this year and -7.90% over the past 12 months. Looking at the last ten years, VRTX has achieved an annualized return of 18.89%, outperforming the S&P 500 Index benchmark, which averaged 12.16% per year.

Based on dividend-adjusted daily data since Jul 24, 1991, VRTX's average daily return is +0.11%, while the average monthly return is +2.18%. At this rate, your investment would double in approximately 2.7 years.

Historically, 54% of months were positive and 46% were negative. The best month was Feb 2000 with a return of +77.2%, while the worst month was Sep 2001 at -51.1%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 7 months.

On a daily basis, VRTX closed higher 48% of trading days. The best single day was Apr 19, 2013 with a return of +61.9%, while the worst single day was Nov 11, 2003 at -36.8%.

Vertex Pharmaceuticals Incorporated has an annualized alpha of 19.08%, beta of 1.07, and R² of 0.12 versus S&P 500 Index. Calculated based on daily prices since July 25, 1991.

• This stock captured 131.66% of S&P 500 Index gains and 105.46% of its losses — amplifying both gains and losses, but participating more in upside than downside.
• R² of 0.12 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

VRTX ranks 29 for risk / return — below 29% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Vertex Pharmaceuticals Incorporated (VRTX) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Vertex Pharmaceuticals Incorporated. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Vertex Pharmaceuticals Incorporated was 91.77%, occurring on Nov 11, 2003. Recovery took 2677 trading sessions.

The current Vertex Pharmaceuticals Incorporated drawdown is 13.59%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Vertex Pharmaceuticals Incorporated over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Vertex Pharmaceuticals Incorporated is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.